Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01928771




Registration number
NCT01928771
Ethics application status
Date submitted
16/08/2013
Date registered
27/08/2013
Date last updated
3/05/2017

Titles & IDs
Public title
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
Scientific title
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting ß2 Agonist in Patients With Uncontrolled Asthma
Secondary ID [1] 0 0
D3250C00017
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Benralizumab
Treatment: Other - Placebo

Experimental: Benralizumab 30 mg q.4 weeks - Benralizumab administered subcutaneously every 4 weeks

Experimental: Benralizumab 30 mg q.8 weeks - Benralizumab administered subcutaneously every 8 weeks

Placebo comparator: Placebo - Placebo administered subcutaneously


Treatment: Other: Benralizumab
Benralizumab subcutaneously on study week 0 until study week 44 inclusive.

Treatment: Other: Placebo
Placebo subcutaneously on study week 0 until study week 44 inclusive.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL
Timepoint [1] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [1] 0 0
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL
Timepoint [1] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [2] 0 0
Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations
Timepoint [2] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [3] 0 0
Number of Patients With >=1 Asthma Exacerbations
Timepoint [3] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [4] 0 0
Time to First Asthma Exacerbation
Timepoint [4] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [5] 0 0
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL
Timepoint [5] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [6] 0 0
Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL
Timepoint [6] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [7] 0 0
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL
Timepoint [7] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [8] 0 0
Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL
Timepoint [8] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [9] 0 0
Change in Asthma Rescue Medication
Timepoint [9] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [10] 0 0
Home Lung Function Assessment Based on Morning PEF
Timepoint [10] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [11] 0 0
Home Lung Function Assessment Based on Evening PEF
Timepoint [11] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [12] 0 0
Proportion of Night Awakening Due to Asthma
Timepoint [12] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [13] 0 0
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL
Timepoint [13] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [14] 0 0
Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL
Timepoint [14] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [15] 0 0
Pharmacokinetics of Benralizumab
Timepoint [15] 0 0
Baseline, week 4, week 4 day 6, week 8, week 16, week 24, week 32, week 40, week 48, week 56
Secondary outcome [16] 0 0
Immunogenicity of Benralizumab
Timepoint [16] 0 0
Pre-treatment until end of follow-up
Secondary outcome [17] 0 0
Extend of Exposure
Timepoint [17] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [18] 0 0
Mean Change From Baseline to Week 48 in AQLQ(S)+12
Timepoint [18] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [19] 0 0
Mean Change From Baseline to Week 48 in EQ-5D-5L VAS
Timepoint [19] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [20] 0 0
Mean Work Productivity Loss Due to Asthma
Timepoint [20] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [21] 0 0
Mean Productivity Loss Due to Asthma in Classroom
Timepoint [21] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [22] 0 0
Number of Participants That Utilized Health Care Resources
Timepoint [22] 0 0
Immediately following the first administration of study drug through Study Week 48.
Secondary outcome [23] 0 0
Patient and Clinician's Responder Assessment to Treatment
Timepoint [23] 0 0
Immediately following the first administration of study drug through Study Week 48

Eligibility
Key inclusion criteria
1. Written informed consent for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent[s]/guardian[s]) and according to international guidelines and/or applicable European Union guidelines.
2. Female and Male aged 12 to 75 years inclusively, at the time of visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.
3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250µg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1
4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral corticosteroids and additional asthma controllers.

* For subjects 18 years of age and older, the ICS dose must be >500 mcg/day fluticasone propionate dry powder formulation or equivalent daily.
* For subjects ages 12-17, the ICS dose must be =500 mcg /day fluticasone propionate dry powder formulation or equivalent daily.
Minimum age
12 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

* Affect the safety of the patient throughout the study
* Influence the findings of the studies or their interpretations
* Impede the patient's ability to complete the entire duration of study
3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/09/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/04/2016
Sample size
Target
Accrual to date
Final
2681
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Bedford Park
Recruitment hospital [2] 0 0
Research Site - Box Hill
Recruitment hospital [3] 0 0
Research Site - Clayton
Recruitment hospital [4] 0 0
Research Site - Concord
Recruitment hospital [5] 0 0
Research Site - Frankston
Recruitment hospital [6] 0 0
Research Site - Nedlands
Recruitment hospital [7] 0 0
Research Site - New Lambton Heights
Recruitment hospital [8] 0 0
Research Site - Parkville
Recruitment hospital [9] 0 0
Research Site - Prahran
Recruitment hospital [10] 0 0
Research Site - Randwick
Recruitment hospital [11] 0 0
Research Site - Woolloongabba
Recruitment postcode(s) [1] 0 0
- Bedford Park
Recruitment postcode(s) [2] 0 0
- Box Hill
Recruitment postcode(s) [3] 0 0
- Clayton
Recruitment postcode(s) [4] 0 0
- Concord
Recruitment postcode(s) [5] 0 0
- Frankston
Recruitment postcode(s) [6] 0 0
- Nedlands
Recruitment postcode(s) [7] 0 0
- New Lambton Heights
Recruitment postcode(s) [8] 0 0
- Parkville
Recruitment postcode(s) [9] 0 0
- Prahran
Recruitment postcode(s) [10] 0 0
- Randwick
Recruitment postcode(s) [11] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Montana
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
North Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
Rhode Island
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
Tennessee
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
West Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Wisconsin
Country [35] 0 0
Brazil
State/province [35] 0 0
Porto Alegre
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio de Janeiro
Country [37] 0 0
Brazil
State/province [37] 0 0
Santo André
Country [38] 0 0
Brazil
State/province [38] 0 0
Sao Paulo
Country [39] 0 0
Brazil
State/province [39] 0 0
Sorocaba
Country [40] 0 0
Brazil
State/province [40] 0 0
São Paulo
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Dupnitsa
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Pernik
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Pleven
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Ruse
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Samokov
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Sliven
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Sofia
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Stara Zagora
Country [49] 0 0
Bulgaria
State/province [49] 0 0
Varna
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Velingrad
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Yambol
Country [52] 0 0
Czech Republic
State/province [52] 0 0
Brno
Country [53] 0 0
Czech Republic
State/province [53] 0 0
Jindrichuv Hradec
Country [54] 0 0
Czech Republic
State/province [54] 0 0
Karlovy Vary
Country [55] 0 0
Czech Republic
State/province [55] 0 0
Ostrava
Country [56] 0 0
Czech Republic
State/province [56] 0 0
Pardubice
Country [57] 0 0
Czech Republic
State/province [57] 0 0
Plzen
Country [58] 0 0
Czech Republic
State/province [58] 0 0
Praha
Country [59] 0 0
Czech Republic
State/province [59] 0 0
Rokycany
Country [60] 0 0
Czech Republic
State/province [60] 0 0
Strakonice
Country [61] 0 0
Czech Republic
State/province [61] 0 0
Teplice
Country [62] 0 0
France
State/province [62] 0 0
Brest Cedex
Country [63] 0 0
France
State/province [63] 0 0
Clermont Ferrand
Country [64] 0 0
France
State/province [64] 0 0
Dijon Cedex
Country [65] 0 0
France
State/province [65] 0 0
Le Kremlin Bicêtre
Country [66] 0 0
France
State/province [66] 0 0
Le Mans Cedex
Country [67] 0 0
France
State/province [67] 0 0
Lyon Cedex 4
Country [68] 0 0
France
State/province [68] 0 0
Marseille
Country [69] 0 0
France
State/province [69] 0 0
Montpellier
Country [70] 0 0
France
State/province [70] 0 0
Paris
Country [71] 0 0
France
State/province [71] 0 0
Pau Cedex
Country [72] 0 0
France
State/province [72] 0 0
Pringy Cedex
Country [73] 0 0
France
State/province [73] 0 0
Saint Pierre
Country [74] 0 0
France
State/province [74] 0 0
Strasbourg Cedex
Country [75] 0 0
France
State/province [75] 0 0
Toulouse
Country [76] 0 0
Italy
State/province [76] 0 0
Bari
Country [77] 0 0
Italy
State/province [77] 0 0
Bologna
Country [78] 0 0
Italy
State/province [78] 0 0
Catania
Country [79] 0 0
Italy
State/province [79] 0 0
Cona
Country [80] 0 0
Italy
State/province [80] 0 0
Firenze
Country [81] 0 0
Italy
State/province [81] 0 0
Foggia
Country [82] 0 0
Italy
State/province [82] 0 0
Legnago
Country [83] 0 0
Italy
State/province [83] 0 0
Milano
Country [84] 0 0
Italy
State/province [84] 0 0
Napoli
Country [85] 0 0
Italy
State/province [85] 0 0
Palermo
Country [86] 0 0
Italy
State/province [86] 0 0
Pavia
Country [87] 0 0
Italy
State/province [87] 0 0
Perugia
Country [88] 0 0
Italy
State/province [88] 0 0
Pisa
Country [89] 0 0
Italy
State/province [89] 0 0
Roma
Country [90] 0 0
Italy
State/province [90] 0 0
San Pietro Vernotico
Country [91] 0 0
Italy
State/province [91] 0 0
Torino
Country [92] 0 0
Italy
State/province [92] 0 0
Verona
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Anyang-si
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Bucheon-si
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Busan
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Cheongju-si
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Gwangju
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Incheon
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Jeju-si
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Seoul
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Suwon-si
Country [102] 0 0
Mexico
State/province [102] 0 0
Guadalajara
Country [103] 0 0
Mexico
State/province [103] 0 0
Monterrey
Country [104] 0 0
Mexico
State/province [104] 0 0
Morelia
Country [105] 0 0
Peru
State/province [105] 0 0
Cusco
Country [106] 0 0
Peru
State/province [106] 0 0
Lima
Country [107] 0 0
Peru
State/province [107] 0 0
Surco
Country [108] 0 0
Poland
State/province [108] 0 0
Bialystok
Country [109] 0 0
Poland
State/province [109] 0 0
Dobre Miasto
Country [110] 0 0
Poland
State/province [110] 0 0
Gdansk
Country [111] 0 0
Poland
State/province [111] 0 0
Gizycko
Country [112] 0 0
Poland
State/province [112] 0 0
Grodzisk Mazowiecki
Country [113] 0 0
Poland
State/province [113] 0 0
Koscian
Country [114] 0 0
Poland
State/province [114] 0 0
Legnica
Country [115] 0 0
Poland
State/province [115] 0 0
Lublin
Country [116] 0 0
Poland
State/province [116] 0 0
Poznan
Country [117] 0 0
Poland
State/province [117] 0 0
Proszowice
Country [118] 0 0
Poland
State/province [118] 0 0
Rzeszów
Country [119] 0 0
Poland
State/province [119] 0 0
Sosnowiec
Country [120] 0 0
Poland
State/province [120] 0 0
Wolomin
Country [121] 0 0
Poland
State/province [121] 0 0
Wroclaw
Country [122] 0 0
Poland
State/province [122] 0 0
Zgierz
Country [123] 0 0
Poland
State/province [123] 0 0
Lódz
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Chelyabinsk
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Ekaterinburg
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Ivanovo
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Izhevsk
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Kazan
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Moscow
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Nizhny Novgorod
Country [131] 0 0
Russian Federation
State/province [131] 0 0
Novosibirsk
Country [132] 0 0
Russian Federation
State/province [132] 0 0
Pyatigorsk
Country [133] 0 0
Russian Federation
State/province [133] 0 0
Rostov-on-Don
Country [134] 0 0
Russian Federation
State/province [134] 0 0
Ryazan
Country [135] 0 0
Russian Federation
State/province [135] 0 0
Saint - Petersburg
Country [136] 0 0
Russian Federation
State/province [136] 0 0
Saint Petersburg
Country [137] 0 0
Russian Federation
State/province [137] 0 0
Saint-Petersburg
Country [138] 0 0
Russian Federation
State/province [138] 0 0
Saratov
Country [139] 0 0
Russian Federation
State/province [139] 0 0
Smolensk
Country [140] 0 0
Russian Federation
State/province [140] 0 0
St. Petersburg
Country [141] 0 0
Russian Federation
State/province [141] 0 0
StPetersburg
Country [142] 0 0
Russian Federation
State/province [142] 0 0
Tomsk
Country [143] 0 0
Russian Federation
State/province [143] 0 0
Vladikavkaz
Country [144] 0 0
Russian Federation
State/province [144] 0 0
Vladimir
Country [145] 0 0
Russian Federation
State/province [145] 0 0
Volgograd
Country [146] 0 0
Russian Federation
State/province [146] 0 0
Yaroslavl
Country [147] 0 0
Russian Federation
State/province [147] 0 0
Yekaterinburg
Country [148] 0 0
South Africa
State/province [148] 0 0
Benoni
Country [149] 0 0
South Africa
State/province [149] 0 0
Cape Town
Country [150] 0 0
South Africa
State/province [150] 0 0
Durban
Country [151] 0 0
South Africa
State/province [151] 0 0
Mowbray
Country [152] 0 0
South Africa
State/province [152] 0 0
Stanger
Country [153] 0 0
Spain
State/province [153] 0 0
Barcelona
Country [154] 0 0
Spain
State/province [154] 0 0
Lugo
Country [155] 0 0
Spain
State/province [155] 0 0
Madrid
Country [156] 0 0
Spain
State/province [156] 0 0
Málaga
Country [157] 0 0
Spain
State/province [157] 0 0
Oviedo
Country [158] 0 0
Spain
State/province [158] 0 0
Palma de Mallorca
Country [159] 0 0
Spain
State/province [159] 0 0
Sagunto(Valencia)
Country [160] 0 0
Spain
State/province [160] 0 0
Salamanca
Country [161] 0 0
Spain
State/province [161] 0 0
Valencia
Country [162] 0 0
Turkey
State/province [162] 0 0
Adana
Country [163] 0 0
Turkey
State/province [163] 0 0
Ankara
Country [164] 0 0
Turkey
State/province [164] 0 0
Antalya
Country [165] 0 0
Turkey
State/province [165] 0 0
Bursa
Country [166] 0 0
Turkey
State/province [166] 0 0
Istanbul
Country [167] 0 0
Turkey
State/province [167] 0 0
Izmir
Country [168] 0 0
Turkey
State/province [168] 0 0
Kocaeli
Country [169] 0 0
Turkey
State/province [169] 0 0
Mersin
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Birmingham
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Bradford
Country [172] 0 0
United Kingdom
State/province [172] 0 0
Cambridge
Country [173] 0 0
United Kingdom
State/province [173] 0 0
Chertsey
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Chester
Country [175] 0 0
United Kingdom
State/province [175] 0 0
Chippenham
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Cottingham
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Darlington
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Glasgow
Country [179] 0 0
United Kingdom
State/province [179] 0 0
High Heaton/Newcastle upon Tyn
Country [180] 0 0
United Kingdom
State/province [180] 0 0
Leeds
Country [181] 0 0
United Kingdom
State/province [181] 0 0
Liverpool
Country [182] 0 0
United Kingdom
State/province [182] 0 0
London
Country [183] 0 0
United Kingdom
State/province [183] 0 0
Maidstone
Country [184] 0 0
United Kingdom
State/province [184] 0 0
Manchester
Country [185] 0 0
United Kingdom
State/province [185] 0 0
Nottingham
Country [186] 0 0
United Kingdom
State/province [186] 0 0
Plymouth
Country [187] 0 0
United Kingdom
State/province [187] 0 0
Portsmouth
Country [188] 0 0
United Kingdom
State/province [188] 0 0
Soham
Country [189] 0 0
United Kingdom
State/province [189] 0 0
Somerset
Country [190] 0 0
United Kingdom
State/province [190] 0 0
Stevenage
Country [191] 0 0
United Kingdom
State/province [191] 0 0
Stockton
Country [192] 0 0
Vietnam
State/province [192] 0 0
Hanoi
Country [193] 0 0
Vietnam
State/province [193] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
Trial website
https://clinicaltrials.gov/study/NCT01928771
Trial related presentations / publications
Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14.
Lugogo NL, Kreindler JL, Martin UJ, Cook B, Hirsch I, Trudo FJ. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Aug;125(2):171-176. doi: 10.1016/j.anai.2020.04.011. Epub 2020 Apr 22.
Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14.
Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020 Jan;124(1):79-86. doi: 10.1016/j.anai.2019.10.006. Epub 2019 Oct 15.
Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23.
Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct 18;52(4):1800936. doi: 10.1183/13993003.00936-2018. Print 2018 Oct.
DuBuske L, Newbold P, Wu Y, Trudo F. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab. Allergy Asthma Proc. 2018 Sep 4;39(5):345-349. doi: 10.2500/aap.2018.39.4162. Epub 2018 Aug 4.
Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018 May;120(5):504-511.e4. doi: 10.1016/j.anai.2018.01.030. Epub 2018 Feb 1.
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
Public notes

Contacts
Principal investigator
Name 0 0
Eugene R. Bleecker, MD, Professor of Medicine
Address 0 0
Center for Genomics and Personalized Medicine Research, Medical Center Boulevard, Winston-Salem, North Carolina 27157
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01928771